Resveratrol

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Resveratrol

A plant polyphenol studied widely, with evidence still short of a clinical recommendation.

Evidence category: Systematic review. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Resveratrol is a polyphenol compound found in red grape skins, red wine, and certain berries, first studied for its antioxidant and anti-inflammatory properties. It has since been tested in a large number of human clinical trials across many conditions, including metabolic syndrome, cardiovascular risk factors, and polycystic ovary syndrome. A systematic review of the accumulated trials concluded that despite two decades of research, poor oral absorption and inconsistent study design have kept the evidence too weak to support any specific clinical recommendation.

Benefits reported in the imported source

• Trials consistently show reductions in inflammatory markers across many study populations
• Some evidence points to improved blood vessel function and metabolic markers in specific conditions
• Generally well tolerated in trials, with mostly mild gastrointestinal side effects reported

Risks and limits

• Natural oral absorption is very poor, and different formulations have shown widely variable blood levels
• No consensus exists on which condition, dose, or duration produces reliable benefit
• Evidence quality across the field is inconsistent, dominated by small, short, early-phase trials

Source bottom line: Resveratrol has one of the largest human trial bases of any dietary supplement, yet after two decades of research the evidence still falls short of supporting a specific clinical use.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 1–5 hours. Walle et al. 2004, Drug Metab Dispos, PMID 14977870 — human oral PK; rapid and extensive metabolism to glucuronide/sulfate conjugates limits free resveratrol exposure Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis - PubMed